Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

S. Cereda, Michele Reni

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Gemcitabine-based chemotherapy provides very limited disease control in the treatment of advanced pancreatic cancer. Approximately half of the patients failing upfront treatment present good performance status and are willing to undergo further treatment. Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m2 until progressive disease. Docetaxel dose intensity was 100% of the intended dose. No grade >2 toxicity was observed. No objective response to treatment was obtained. Median progression-free survival was 1.5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.

Original languageEnglish
Pages (from-to)509-512
Number of pages4
JournalJournal of Chemotherapy
Volume20
Issue number4
Publication statusPublished - Aug 2008

Fingerprint

docetaxel
gemcitabine
Salvage Therapy
Pancreatic Neoplasms
Therapeutics
Drug Therapy
Disease-Free Survival
Adenocarcinoma
Survival

Keywords

  • Chemotherapy
  • Docetaxel
  • Metastatic disease
  • Pancreatic cancer
  • Salvage therapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Pharmacology

Cite this

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. / Cereda, S.; Reni, Michele.

In: Journal of Chemotherapy, Vol. 20, No. 4, 08.2008, p. 509-512.

Research output: Contribution to journalArticle

@article{deaa8155c40542648a4752b85c30de1f,
title = "Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer",
abstract = "Gemcitabine-based chemotherapy provides very limited disease control in the treatment of advanced pancreatic cancer. Approximately half of the patients failing upfront treatment present good performance status and are willing to undergo further treatment. Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m2 until progressive disease. Docetaxel dose intensity was 100{\%} of the intended dose. No grade >2 toxicity was observed. No objective response to treatment was obtained. Median progression-free survival was 1.5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.",
keywords = "Chemotherapy, Docetaxel, Metastatic disease, Pancreatic cancer, Salvage therapy",
author = "S. Cereda and Michele Reni",
year = "2008",
month = "8",
language = "English",
volume = "20",
pages = "509--512",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

AU - Cereda, S.

AU - Reni, Michele

PY - 2008/8

Y1 - 2008/8

N2 - Gemcitabine-based chemotherapy provides very limited disease control in the treatment of advanced pancreatic cancer. Approximately half of the patients failing upfront treatment present good performance status and are willing to undergo further treatment. Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m2 until progressive disease. Docetaxel dose intensity was 100% of the intended dose. No grade >2 toxicity was observed. No objective response to treatment was obtained. Median progression-free survival was 1.5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.

AB - Gemcitabine-based chemotherapy provides very limited disease control in the treatment of advanced pancreatic cancer. Approximately half of the patients failing upfront treatment present good performance status and are willing to undergo further treatment. Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m2 until progressive disease. Docetaxel dose intensity was 100% of the intended dose. No grade >2 toxicity was observed. No objective response to treatment was obtained. Median progression-free survival was 1.5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.

KW - Chemotherapy

KW - Docetaxel

KW - Metastatic disease

KW - Pancreatic cancer

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=52249103952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249103952&partnerID=8YFLogxK

M3 - Article

C2 - 18676234

AN - SCOPUS:52249103952

VL - 20

SP - 509

EP - 512

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -